Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.40 |
| ▸ | CNR2 | P34972 | 15/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743837 | 0.97 | CNR1 (0.42) | CNR1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL1742966 | 0.93 | CNR1 (0.37) | CNR1CNR2LMNASMN1; SMN2 | |
| SCHEMBL1742605 | 0.93 | CNR1 (0.37) | CNR1CNR2LMNASMN1; SMN2 | |
| SCHEMBL14454992 | 0.90 | CNR1 (0.42) | CNR1CNR2 | |
| SCHEMBL2610726 | 0.87 | CNR1 (0.41) | CNR1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL1742923 | 0.86 | CNR1 (0.41) | CNR1CNR2LMNASMN1; SMN2KMT2A | |
| SCHEMBL2610780 | 0.85 | CNR1 (0.36) | CNR1CNR2LMNASMN1; SMN2KMT2A | |
| SCHEMBL1742965 | 0.83 | CNR1 (0.43) | CNR1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL14454977 | 0.83 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL12161254 | 0.82 | CNR1 (0.35) | CNR1CNR2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | CNR1 4654/4885CNR2 4833/4885LMNA 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.